Becton, Dickinson and Company (NYSE:BDX) Stake Cut by Stonegate Investment Group LLC

Stonegate Investment Group LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 25.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,774 shares of the medical instruments supplier’s stock after selling 1,627 shares during the quarter. Stonegate Investment Group LLC’s holdings in Becton, Dickinson and Company were worth $1,164,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its holdings in Becton, Dickinson and Company by 95,813.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock worth $1,028,807,000 after buying an additional 4,041,425 shares during the last quarter. Norges Bank acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $697,398,000. Ontario Teachers Pension Plan Board boosted its holdings in Becton, Dickinson and Company by 242.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock worth $461,158,000 after purchasing an additional 1,263,391 shares in the last quarter. PineStone Asset Management Inc. increased its position in Becton, Dickinson and Company by 262.0% during the third quarter. PineStone Asset Management Inc. now owns 847,448 shares of the medical instruments supplier’s stock worth $219,091,000 after buying an additional 613,369 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Becton, Dickinson and Company by 86.6% during the second quarter. Marshall Wace LLP now owns 1,196,061 shares of the medical instruments supplier’s stock valued at $315,772,000 after buying an additional 555,090 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $241.02 on Wednesday. The stock’s 50 day simple moving average is $239.89 and its 200-day simple moving average is $244.36. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The stock has a market cap of $69.63 billion, a PE ratio of 57.11, a P/E/G ratio of 2.04 and a beta of 0.43. Becton, Dickinson and Company has a 1 year low of $229.85 and a 1 year high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same quarter in the previous year, the firm posted $2.98 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Raymond James upped their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays upped their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus price target of $279.17.

Read Our Latest Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.